In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MedImmune next-generation FluMist

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

MedImmune has initiated a pivotal Phase III head-to-head study comparing its next-generation, refrigerator-stable formulation of its intranasal flu vaccine FluMist to the trivalent injectable vaccine, the firm says Oct. 20. FluMist is a frozen, live, attenuated trivalent vaccine. The double-blind study will enroll 7,000 children between the ages of 6 and 59 months. A bridging study is also being conducted to establish the new cold-adapted intranasal formulation (CAIV-T) as equivalent to frozen FluMist. MedImmune has already conducted two Phase III trials in 4,400 children with a history of respiratory illness or asthma; data were presented at the Pediatric Academic Societies' annual meeting in May...

You may also be interested in...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts